Skip to main content

Table 1 Baseline characteristics of trial participants by treatment arma

From: The effect of standard dose multivitamin supplementation on disease progression in HIV-infected adults initiating HAART: a randomized double blind placebo-controlled trial in Uganda

Characteristic MVa (n = 200) Placebo (n = 200)
Sex Males 57 (28.5 %) 66 (33.0 %)
Females 143 (71.5 %) 134 (67.0 %)
Age (years) 18–20 9 (4.5 %) 1 (0.5 %)
21–30 42 (21.0 %) 58 (29.0 %)
31–40 85 (42.5 %) 100 (50.0 %)
>40 64 (32.0 %) 41 (20.5 %)
Mean ± SDb 36.9 ± 9.6 34.7 ± 8.1
Level of education None 7 (3.0 %) 6 (3.0 %)
Primary 103 (51.5 %) 103 (51.5 %)
Secondary 70 (35.0 %) 71 (35.5 %)
> Secondary 20 (10.0 %) 20 (10.0 %)
Marital status Never Married 19 (9.5 %) 22 (11.0 %)
Married/cohabiting 86 (43.0 %) 83 (41.5 %)
Separated/divorced 64 (32.0 %) 59 (29.5 %)
Widowed 31 (15.5 %) 36 (18.0 %)
HB (g/dL) ≤11.0 45 (22.5 %) 46 (23.0 %)
>11.0 155 (77.5 %) 154 (77.0 %)
Median (IQR)b 12.2 (11.2–13.2) 12.3 (11.3–13.5)
BMI (kg/m-sq) <18.5 15 (7.5 %) 16 (8.0 %)
18.5–24.9 122 (61.0 %) 136 (68.0 %)
25.0–29.9 43 (21.5 %) 29 (14.5 %)
≥30 17 (8.5 %) 19 (9.5 %)
Missing 3 (1.5 %) 0 (0.0 %)
Time on ART (months) 0 93 (46.5 %) 108 (54.0 %)
1–2 60 (30.0 %) 57 (28.5 %)
3–6 47 (23.5 %) 35 (17.5 %)
Median (IQR)b 1 (0–2) 0 (0–1)
CD4 count (cells/mm3) ≤50 24 (12.0 %) 39 (19.5 %)
51–100 42 (21.0 %) 40 (20.0 %)
101–200 77 (38.5 %) 73 (36.5 %)
>200 53 (26.5 %) 46 (23.0 %)
Missing 4 (2.0 %) 2 (1.0 %)
Median (IQR)b 144.5 (86.0–215.3) 137.0 (68.0–192.0)
MV use duration (months) 0 159 (79.5 %) 153 (76.5 %)
1–2 36 (18.0 %) 42 (21.0 %)
>2 5 (2.5 %) 5 (2.5 %)
  1. aART antiretroviral therapy, HB Hemoglobin, MV Multivitamin supplementation
  2. bVariable treated as continuous variable